#USA #San Diego #Kenai Therapeutics #RNDP-001 #Blake Arnold

Kenai Therapeutics Appoints Blake Arnold as New Chief Business Officer

Kenai Therapeutics, a forward-thinking entity in clinical-stage biotechnology, has announced the significant appointment of Blake Arnold, CFA, as its Chief Business Officer. This decision marks an important milestone as the company, known for its innovative approaches in treating neurological disorders, aims to evolve further.

In his new capacity, Blake Arnold will oversee various initiatives, encompassing business development, financing, strategic partnerships, and corporate development strategies. The leadership at Kenai views his addition as pivotal for the organization, particularly in the context of enhancing clinical and pipeline advancements. According to Nick Manusos, the CEO of Kenai Therapeutics, Arnold is considered an exceptional addition to the team, owing to his vast experience and proven success in navigating strategic transactions specifically within the biotechnology and therapy sectors.

Blake Arnold brings nearly two decades of wealth in biopharmaceuticals and life science industries, encasing roles in corporate strategy, venture capital, and equity research. His most recent position was as Vice President of M&A Transactions at Novartis AG, where he led a variety of strategic acquisitions. Before this, he held progressive roles at Novartis Gene Therapies, previously known as AveXis, where he thought-lead a comprehensive strategy for portfolio innovation and business development.

Prior to his expansive tenure at Novartis, Mr. Arnold contributed to Baxter International in global business development and corporate venture capital, executing essential tasks such as due diligence and deal initiation. He began his professional journey as an equity research analyst covering the biotechnology sector at Robert W. Baird & Co., further refining his expertise in the field.

Educationally, Arnold possesses a Bachelor’s degree in Business Administration, with a focus in Finance, earned from the University of Wisconsin-Madison. He later acquired a Master of Business Administration from the prestigious Kellogg School of Management at Northwestern University.

About Kenai Therapeutics

Founded in 2022, Kenai Therapeutics operates at the frontier of biotechnology, developing novel solutions aimed at curing neurological conditions. Their cutting-edge pipeline is rooted in a proprietary induced pluripotent stem cells (iPSC) platform, recognized by a Nobel Prize. This forefront technology focuses on creating allogeneic neuron replacement and gene-modified cell therapies which are designed to be disease-modifying. Currently, their flagship candidate, RNDP-001, is undergoing Phase 1 clinical trials targeting moderate to severe idiopathic Parkinson's disease, with additional programs seeking solutions for genetically driven types of Parkinson's as well as other neurological conditions.

With an exclusive manufacturing partnership with FUJIFILM Cellular Dynamics, Inc., Kenai aims for scalable, cryopreserved production of high-potency therapies, enhancing its capabilities for delivering lasting results in neurological restoration. As Kenai advances, it stands backed by leading investors in life sciences, continuously working to redefine the future landscape of neurological treatment.